Skip to content
Menu

Danaher Corporation DHR

Full chart Compare
Set alert

Price alert · DHR

All alert types
233.02 USD +0.86 (+0.37%)

Regular-session close

233.02 0.00 0.00%

After hours · Nov 13, 5:21 PM ET

229.92 Day range 233.76
161.91 52-week range 242.05
YTD
+1.79%
1 year
+5.34%

Discussion (160)

Sign in to join the discussion

Mark Keller DHR 5 years ago #141

April 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company's previously communicated guidance range.

For the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%. The better-than-expected performance was broad-based across the portfolio, with particular strength in Life Sciences and Diagnostics.

Mark Keller DHR 5 years ago #142

DHR....

DANAHER PROVIDES UPDATE ON FIRST QUARTER 2021 FINANCIAL PERFORMANCE
WASHINGTON, April 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company's previously communicated guidance range.

For the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%. The better-than-expected performance was broad-based across the portfolio, with particular strength in Life Sciences and Diagnostics.

Mark Keller DHR 5 years ago #143

DANAHER PROVIDES UPDATE ON FIRST QUARTER 2021 FINANCIAL PERFORMANCE
WASHINGTON, April 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company's previously communicated guidance range.

For the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%. The better-than-expected performance was broad-based across the portfolio, with particular strength in Life Sciences and Diagnostics.

Mark Keller DHR 5 years ago #144

Earnings will greatly exceed target. DHR will raise guidance for rest of year. It will be huge according to their release statement earlier this week.

Mark Keller DHR 5 years ago #145

DHR raised Q1 guidance to overachieve high end of target. My expectations are huge numbers next Thursday PLUS raised guidance for the remainder of the year. Stock is up about 3% for year. Expect minimum average year increase of 12% price and will probably return 18-20% this year. That puts PT at >$275 eoy.

Mark Keller DHR 5 years ago #146

Now is the time to load up, before next weeks blowout earnings. DHR $250+ by next Friday.

Mark Keller DHR 5 years ago #147

DHR has been a core holding of mine for 15 years. I was a director there. They just dont fail. It is a shareholders dream foundation stock. 265-275 eoy.

Mark Keller DHR 5 years ago #148

I have never seen DHR stock act like this, in 20 years. Whats going on? Is it just too high valuation?

Mark Keller DHR 5 years ago #149

Execs selling shares in DHR is entirely normal and should have zero bearing on the price of this stock. The amount of options awarded to them, the time limit to exercise, and taxes all are considered when deciding to exercise the options. Other companies this would be a warning sign. Not with DHR. I was a Director there for 7 years.

Mark Keller DHR 5 years ago #150

One of the best companies to own, period. I was a director their for 7 years. The culture produces results.